A universal genetic testing initiative for patients with high-grade, non-mucinous epithelial ovarian cancer and the implications for cancer treatment.

Main|Search|PHGKB


Last Posted: Jul 17, 2017

---

• A universal genetic testing initiative for patients with high-grade, non-mucinous epithelial ovarian cancer and the implications for cancer treatment.  
  Bednar Erica M et al. Gynecologic oncology 2017 Jun
• Take Action to Lower Your Breast and Ovarian Cancer Risk  
• Current condition of genetic medicine for hereditary breast cancer.  
  Terui-Kohbata Hiroko et al. Molecular and clinical oncology 2017 Jul 7(1) 98-102
• Influence of the Angelina Jolie Announcement and Insurance Reimbursement on Practice Patterns for Hereditary Breast Cancer.  
  Lee Jihyoun et al. Journal of breast cancer 2017 Jun 20(2) 203-207
• Recent Patterns in Genetic Testing for Breast and Ovarian Cancer Risk in the U.S.  
  Han Xuesong et al. American journal of preventive medicine 2017 Jun
• Age-specific overall risk of breast, ovarian cancer among women with BRCA1/2 genetic mutations  
  Science Mag, June 20, 2017
• An integrated model of clinical information and gene expression for prediction of survival in ovarian cancer patients.  
  Yang Rendong et al. Translational research : the journal of laboratory and clinical medicine 2016 Jun 17284-95.e11
• BRCA1-2 diagnostic workflow from next-generation sequencing technologies to variant identification and final report.  
  Pilato Brunella et al. Genes, chromosomes & cancer 2016 Oct 55(10) 803-13
• Breast and Ovarian Cancer Penetrance Estimates Derived From Germline Multiple-Gene Sequencing Results in Women  
  AW Kurian, JCO Precision Oncology, June 27, 2017
• Development and validation of a variant detection workflow for BRCA1 and BRCA2 genes and its clinical application based on the Ion Torrent technology.  
  Buzolin Ana Lígia et al. Human genomics 2017 Jun 11(1) 14
• Mutation detection rates associated with specific selection criteria for BRCA1/2 testing in 1854 high-risk families: A monocentric Italian study.  
  Azzollini Jacopo et al. European journal of internal medicine 2016 Jul 3265-71
• The Changing Landscape of Genetic Testing for Inherited Breast Cancer Predisposition.  
  Afghahi Anosheh et al. Current treatment options in oncology 2017 May 18(5) 27
• Breast and Ovarian Cancer Penetrance Estimates Derived From Germline Multiple-Gene Sequencing Results in Women  
  AW Kurian, JCO Precision Oncology, June 27, 2017
• Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA)  
  The Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA) is a computer program that is used to calculate the risks of breast and ovarian cancer in women based on their family history.
• Predictability of BRCA1/2 mutation status in patients with ovarian cancer: How to select women for genetic testing in middle-income countries.  
  Teixeira Natalia et al. Maturitas 2017 Jun
• Preferences for breast cancer risk reduction among BRCA1/BRCA2 mutation carriers: a discrete-choice experiment.  
  Liede Alexander et al. Breast cancer research and treatment 2017 Jun

more